Inmune Bio, Inc.
INMB Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$1.43
KIRA · Stoqly’s AI analyst, in plain words
- Inmune Bio, Inc. had $0.1M of revenue in fiscal 2025, up 257.1% on the year before. Over five years, revenue changed +35.4% a year on average.
- Its operating margin was −94,766.0%, up 209,769.7 pts: of every 100 in sales, about −94,766 is left after running the business.
- Inmune Bio, Inc. lost $45.9M in fiscal 2025.
- Free cash flow was −$23.6M in fiscal 2025, −47,248.0% of revenue.
Market cap
$38.2M
P/E
—
Revenue
$0.1M
Net income
−$45.9M
Free cash flow
−$23.6M
Operating margin
−94,766.0%
Inmune Bio, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+257.1%
Yes. Sales grew 257.1% last year.
Does it make a profit?
−91,866.0%
No. It lost money last year.
Does profit turn into cash?
−47,248.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Inmune Bio, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Inmune Bio, Inc.
- CIK
- 0001711754
Inmune Bio, Inc. · INMB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.2M | $0.4M | $0.2M | $0.0M | $0.1M |
| Revenue growth | 1,545.5% | 106.6% | −58.6% | −91.0% | 257.1% |
| Operating margin | −16,106.6% | −6,938.8% | −19,187.7% | −304,535.7% | −94,766.0% |
| Net income | −$30.3M | −$27.3M | −$30.0M | −$42.1M | −$45.9M |
| Net margin | −16,762.4% | −7,299.2% | −19,360.0% | −300,585.7% | −91,866.0% |
| Diluted EPS | −$1.88 | −$1.52 | −$1.67 | −$2.11 | −$1.86 |
| Cash | |||||
| Cash from operations | −$28.5M | −$22.7M | −$12.0M | −$33.4M | −$22.6M |
| Capital expenditure | — | — | — | — | $1.0M |
| Free cash flow | — | — | — | — | −$23.6M |
| FCF margin | — | — | — | — | −47,248.0% |
| Share count change | 34.5% | 11.1% | 0.3% | 10.9% | 24.1% |
| Debt and strength | |||||
| Cash and short-term investments | $74.8M | $52.2M | $35.8M | $20.9M | $24.8M |
| Debt incl. finance leases | $15.0M | $15.0M | $9.9M | $15.0M | — |
| Shareholders' equity | $80.2M | $60.1M | $37.3M | $32.1M | $23.5M |
| Current ratio | 19.0x | 5.9x | 2.2x | 3.1x | 3.6x |
| Interest coverage | −29.6x | −12.9x | −13.1x | −119.4x | — |
| Returns and quality | |||||
| Return on capital | −112.8% | −89.3% | −205.9% | −128.7% | — |
| Return on equity | −51.0% | −38.9% | −61.6% | −121.2% | −165.2% |
| Return on tangible equity | −47.6% | −62.6% | −144.1% | −270.1% | −195.3% |
| Piotroski F-score | 3 | 2 | 2 | 2 | 3 |
| Altman Z'' | 5.4 | 1.5 | −5.9 | −13.6 | −23.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Inmune Bio, Inc. · INMB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.43 a share, the company is worth $38.2M.
Source: SEC EDGAR XBRL filings (CIK 0001711754). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.